Abexinostat Active in R/R Follicular Lymphoma

Share this content:
Abexinostat had significant clinical activity and was well tolerated overall in patients with relapsed/refractory follicular lymphoma.
Abexinostat had significant clinical activity and was well tolerated overall in patients with relapsed/refractory follicular lymphoma.

Abexinostat, an oral pan-histone deacetylase inhibitor (HDACi), had significant clinical activity and was well tolerated overall in patients with relapsed/refractory follicular lymphoma, a study published in the journal Clinical Cancer Research has shown.1

Because additional targeted agents are needed for the treatment of lymphoma, and HDACi have demonstrated efficacy in cutaneous T-cell lymphoma, researchers sought to evaluate abexinostat in relapsed/refractory lymphoma.

For the phase 1 portion, researchers enrolled 25 heavily pretreated patients with any lymphoma subtype. All participants received abexinostat 30 to 60 mg/m2 orally twice daily 5 days per week for 3 weeks or 7 days per week every other week. The maximum tolerated dose was determined to be 45 mg/m2 twice daily 7 days per week administered every other week.

For the phase 2 study, researchers enrolled 30 patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma. All received the recommended dose identified in phase 1.

Results showed that overall response rate was 64.3% among the 25 evaluable patients. Researchers found that median progression-free survival was 20.5 months and median duration of response had not yet been reached.

For patients specifically with follicular lymphoma, 89% received treatment for more than 8 months.

Those with mantle cell lymphoma had an overall response rate of 27.3% and a median progression-free survival of 3.9 months.

RELATED: Early MRI-based Screening May Reduce Breast Cancer Mortality Among Lymphoma Survivors

In terms of safety, the most common grade 3 to 4 treatment-related adverse events were thrombocytopenia, fatigue, and neutropenia. Of note, researchers observed an occurrence of QTc prolongation, but it was rare.

Reference

  1. Evens AM, Balasubramanian S, Vose JM, et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clin Cancer Res. 2016;22:1059.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs